Compass therapeutics reports 2025 second quarter financial results and provides corporate update

Boston, aug. 11, 2025 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs.
CMPX Ratings Summary
CMPX Quant Ranking